Fundraising Fox
/Companies
Sign in

Phagenesis

8 known investors

Find your way into Phagenesis

Sign up to find every way you can get introduced to Phagenesis

  • Your email: who you already know at Phagenesis, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Phagenesis team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Phagenesis develops targeted pharyngeal electrical stimulation technology to treat neurogenic dysphagia by restoring neural pathways for safe swallowing. The company serves patients with swallowing disorders caused by neurological conditions, supported by 25 years of clinical research and evidence.

Deep TechDigital HealthHealthtechMedical Devices

Investors · 8

Innvotec Ltd.listed by Innvotec Ltd.London · $317.5K – $635K
Northern Gritstonelisted by Northern GritstoneManchester

How we know: Northern Gritstone's portfolio page · uktech.news · the VCSheet dataset · Not right? Tell us

EQT Life SciencesreportedLuxembourg · $11M – $66M

How we know: funding news · phagenesis.com · Not right? Tell us

Sectoral Asset ManagementreportedMontreal

How we know: funding news · phagenesis.com · Not right? Tell us

Also in the syndicate · 3

AphelionBritish Patient Capital Future FundSectoral

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Phagenesis went on to found or lead other companies.

Oern R. StugeChairmanFounded Impulse Dynamics +1Daniel GreenCEOFounded Precision Microbubbles

In the news

Phagenesis Appoints Chad Hoskins as Chief Executive Officer Following Recent Close of $42M Series D Financing - Phagenesisphagenesis.com · Sep 2024Phagenesis Successfully Closes a $42M Series D Financing Round Led by EQT Life Sciences and Sectoral Asset Management - Phagenesisphagenesis.com · Mar 2024

Frequently asked questions

What does Phagenesis do?
Phagenesis develops targeted pharyngeal electrical stimulation technology to treat neurogenic dysphagia by restoring neural pathways for safe swallowing. The company serves patients with swallowing disorders caused by neurological conditions, supported by 25 years of clinical research and evidence.
Who are Phagenesis's investors?
Phagenesis's investors include Aphelion Capital, Innvotec Ltd., Northern Gritstone, EQT Life Sciences, Sectoral Asset Management.